Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on June 8, 2018, with the earliest event reported on that date. The filing details amendments to the company's capital structure and the closing of a public securities offering.
Key Financial Metrics and Capital Structure
- Public Offering Proceeds: The company closed a public offering totaling $18,000,000.
- Securities Issued: The offering consisted of 9,140,000 Class A Units and 8,860 Class B Units.
- Series B Preferred Stock: 8,860 shares designated with a stated value of $1,000 per share.
- Conversion Terms: Series B Preferred Stock is convertible into common stock at $1.00 per share, subject to a 4.99% (or 9.99% upon election) beneficial ownership limitation.
- Over-Allotment: Underwriters partially exercised their option, purchasing an additional 2,700,000 warrants. A remaining option exists to purchase up to 2,700,000 shares of common stock and/or warrants within 45 days.
- Operating Metrics: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the authorization and issuance of Series B Convertible Preferred Stock and the successful closing of the $18 million public offering. This represents a significant increase in the company's authorized capital and cash resources compared to the prior period, though specific pre-offering balance sheet data is not included in this report.
Guidance, Outlook, and Risks
- Management Commentary: The filing references a press release (Exhibit 99.1) regarding the offering closing but does not contain forward-looking guidance or management discussion within the text provided.
- Risks and Contingencies: The Series B Preferred Stock includes specific voting rights and liquidation preferences. Holders are entitled to vote on an as-converted basis but are restricted by the beneficial ownership limitation. No dividends are payable unless declared by the Board.
- Unusual Items: The structure involves a dual-class unit offering (Class A and Class B) alongside the creation of a new preferred stock series.
Investor Verification Checklist
- Verify the final use of the $18,000,000 proceeds in subsequent financial statements.
- Confirm the exercise status of the remaining 45-day over-allotment option for shares and warrants.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for detailed rights and limitations of the Series B Preferred Stock.
- Check for any subsequent filings regarding the conversion of Series B Preferred Stock into common stock.